Viragen Reports on Multiferon Anti-Viral Studies with U.S. Army Researchers
Viragen, Inc. and its majority-owned subsidiary, Viragen International, Inc., reported on the progression of anti-viral studies using Multiferon® (multi-subtype, natural human alpha interferon) being conducted by the U.S. Army Medical Research Institute of infectious diseases (USAMRIID). These studies have found Multiferon® to have significant activity when used in vitro against certain "Category A" pathogens, a class of highly virulent viral threats, which have the potential to be used in biowarfare.
In this research collaboration, Viragen and USAMRIID have agreed to conduct a study program designed to evaluate Multiferon® against specific viral agents. Additional studies will evaluate Multiferon® as a possible broad-acting anti-viral product, which may be used as a first-line of defense against unknown infectious agents or when no therapeutic or vaccine exists. These studies are expected to be completed by this summer and will help determine the potential role of Multiferon® as a bio-defense product.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
